Table 4.
Level of endorsement of common domains reported by DLBCL patients treated with CAR T therapy
| Conceptual domain | Degree of endorsement | ||||||
|---|---|---|---|---|---|---|---|
| EORTC QLQ-C30 | EQ-5D | WPAI | PROMIS-29 | MFI | FACT-G | FACT-LYMc | |
| Physical functioning | Higha | High | NAb | High | NA | High | High |
| Emotional functioning | High | High | NA | High | NA | High | High |
| Fatigue | High | NA | NA | NA | High | High | High |
| Social functioning | High | NA | NA | High | NA | High | High |
| Role functioning | High | NA | High | NA | NA | NA | NA |
| Cognitive functioning | Moderate | NA | NA | NA | NA | NA | NA |
| Pain/discomfort | Moderate | Moderate | NA | Moderate | NA | Moderate | Moderate |
| Sleep | Moderate | NA | NA | Moderate | NA | NA | NA |
| General symptoms | Moderate | NA | NA | NA | NA | Moderate | Moderate |
CAR T chimeric antigen receptor T-cell, DLBCL diffuse large B-cell lymphoma, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, EQ-5D EuroQoL 5-Dimension, FACT-LYM Functional Assessment of Cancer Therapy-Lymphoma, FACT-G Functional Assessment of Cancer Therapy-General, MFI Multidimensional Fatigue Inventory, PRO patient-reported outcome, PROMIS-29 Patient-Reported Outcomes Measurement Information System-29, WPAI Work Productivity and Activity Impairment
aHigh endorsement was classified as > 50% patient endorsement, moderate endorsement as 25–50% patient endorsement, and low endorsement as < 25% patient endorsement
bNA = Not applicable, as PRO did not have the domain
cThe lymphoma-specific symptom domain of the FACT-LYM was not included in this analysis